Prospective Trial of Tranexamic Acid in Cardiac Surgery
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Tranexamic acid, an antifibrinolytic drug, is wildly used in cardiac surgeries to decrease
perioperative bleeding and allogenic transfusion. But the optimum dose of tranexamic acid is
still unknown. We use three different doses to find which is the optimum dose of tranexamic
acid in cardiopulmonary bypass cardiac surgery.